SCHEMBL6030592

SCHEMBL6030592

CCCCCCCCNC(=O)Nc1sc(C(=O)N(CC)c2cccnc2)c(C)c1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.45
HPGD P15428 4/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
FLT4 P35916 2/20 0.41
CDK2 P24941 1/20 0.41
HTT P42858 2/20 0.40
HDAC6 Q9UBN7 1/20 0.40
EPHX1 P07099 6/20 0.40
MAPT P10636 2/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2B6 P20813 1/20 0.36
CYP2C19 P33261 1/20 0.36
FES P07332 1/20 0.36
RET P07949 1/20 0.36
MARK3 P27448 1/20 0.36
TYK2 P29597 1/20 0.36
SYK P43405 1/20 0.36
CLK2 P49760 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6031608 0.89 ALDH1A1 (0.47) ALDH1A1HPGDSMN1; SMN2FLT4CDK2
SCHEMBL6030084 0.82 CHRM4 (0.45) ALDH1A1HPGDSMN1; SMN2FLT4CDK2
SCHEMBL6030294 0.81 FLT4 (0.52) ALDH1A1HPGDSMN1; SMN2FLT4CDK2
SCHEMBL6030355 0.78 ALDH1A1 (0.48) ALDH1A1HPGDSMN1; SMN2HTTEPHX1
SCHEMBL6030364 0.77 EPHX1 (0.45) ALDH1A1HPGDHTTEPHX1MAPT
SCHEMBL6030772 0.77 EPHX1 (0.46) ALDH1A1HPGDHTTEPHX1MAPT
SCHEMBL6030371 0.77 EPHX1 (0.46) ALDH1A1HPGDHTTEPHX1MAPT
SCHEMBL6030269 0.77 EPHX1 (0.46) ALDH1A1HPGDHTTEPHX1MAPT
SCHEMBL6030406 0.77 EPHX1 (0.46) ALDH1A1HPGDHTTEPHX1MAPT
SCHEMBL6030458 0.77 EPHX1 (0.48) ALDH1A1HPGDHTTEPHX1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL ALDH1A1 1832/4885HPGD 4273/4885SMN1; SMN2 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.